Drug Approval | April 20, 2026
Aurobindo Pharma bags USFDA nod for Glycerol Phenylbutyrate Oral Liquid
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
The approved product is a generic version of Ravicti, originally developed and marketed by Horizon Therapeutics
GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved
Safety was equally impressive. ENV-294 was well tolerated
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
The results, published in The Lancet, showed orforglipron delivered significantly greater reductions in both A1C and body weight across primary and key secondary endpoints
Subscribe To Our Newsletter & Stay Updated
